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Materials	  and	  Methods	  
	  
1.	  Fibril	  sonication	  
Recombinant	  wildtype	  mouse	  α-­‐synuclein	  fibrils	  were	  generated	  as	  previously	  published	  (Luk	  et	  al.,	  2012a;	  Luk	  et	  al.,	  
2012b;	  Luk	  et	  al.,	  2009;	  Volpicelli-­‐Daley	  et	  al.,	  2014;	  Volpicelli-­‐Daley	  et	  al.,	  2011).	  As	  fibril	  sonication	  parameters	  are	  
extremely	   important	   in	   the	   transmission	   of	   pathology	   (Volpicelli-­‐Daley	   et	   al.,	   2014),	   we	   used	   two	   different	  
sonication	   techniques.	   First,	   we	   sonicated	   fibrils	   with	   a	   probe	   sonicator	   (Misonix	   model	   XL2020,	   Misonix	  
Incorporated,	  Farmingdale	  NY)	  for	  sixty	  0.5	  sec	  pulses	  with	  a	  pause	  every	  10	  pulses	  to	  let	  the	  solution	  cool	  (~1	  min	  
total).	   The	   total	   volume	   sonicated	   with	   the	   probe	   was	   approximately	   75	   μL.	   For	   the	   alternative	   waterbath	  
sonication,	  we	  sonicated	  approximately	  10	  μL	  of	  sample	  (5	  mg/mL)	  in	  a	  0.5	  mL	  centrifuge	  tube,	  continuously	  for	  1h	  
or	  for	  24h	  (Bransonic	  series	  model	  M1800,	  Branson	  Ultrasonics	  Corporation,	  Danbury	  CT).	  It	  is	  worth	  noting	  that	  this	  
sonicator	  is	  inexpensive	  relative	  to	  what	  is	  commonly	  used	  for	  fibril	  sonication	  in	  the	  literature.	  	  Fibril	  stock	  solutions	  
were	  frozen,	  but	  were	  not	  placed	  on	  ice	  during	  or	  after	  sonication.	  During	  waterbath	  sonication,	  Parafilm	  was	  thickly	  
wrapped	  around	  the	  tube	  lid	  to	  prevent	  any	  entry	  of	  aerosolized	  water	   into	  the	  tube.	  Fibril	  sonication	  was	  always	  
completed	   within	   approximately	   ~0.5-­‐4	   hours	   of	   direct	   infusion	   into	   the	   central	   nervous	   system.	   The	   remaining	  
fibrils	  were	  discarded	  after	  the	  infusions	  were	  complete	  and	  no	  solutions	  were	  reused.	  
	  
2.	  Animals	  and	  fibril	  infusions	  	  
Considerable	  efforts	  were	  made	  to	  minimize	  pain	  and	  suffering	  and	  the	  number	  of	  animals	  sacrificed	  was	  kept	  to	  the	  
very	   minimum.	   All	   procedures	   were	   approved	   by	   the	   Duquesne	   University	   Institutional	   Animal	   Care	   and	   Use	  
Committee	   (IACUC	  protocol	  1403-­‐03)	  and	   in	  compliance	  with	   the	  NIH	  Guide.	  Following	   IACUC	  approval,	  male	  CD1	  
mice	  from	  Charles	  River	  were	  bred	  in	  the	  Duquesne	  University	  animal	  facility.	  All	  animals	  were	  group-­‐housed	  with	  
free	   access	   to	   food	   and	   water	   in	   a	   12:12	   hour	   photoperiod.	   Mice	   were	   injected	   with	   one	   microliter	   of	   sterile	  
phosphate-­‐buffered	   saline	   (PBS)	   or	   5	   μg	   preformed	   α-­‐synuclein	   fibrils	   of	   wild-­‐type	   mouse	   origin,	   as	   described	  
previously	  (Luk	  et	  al.,	  2012a).	  Unilateral	   injections	  were	  made	  in	  the	  OB/AON	  (AP	  +4.0,	  ML	  -­‐1.0,	  DV	  -­‐2.5	  mm	  from	  
top	  of	  the	  skull	  at	  bregma)	  or	  the	  hippocampus	  (AP	  -­‐2.5,	  ML	  -­‐2.8,	  DV	  -­‐3.6	  mm	  from	  top	  of	  the	  skull	  at	  bregma).	  All	  
coordinates	   were	   first	   verified	   by	   injecting	   blue	   food	   dye	   into	   the	   targeted	   structure	   and	   ensuring	   accurate	  
placement	   of	   the	   infusate.	   Unlike	   Rey	   and	   colleagues,	  we	   targeted	   the	   rostral	   AON	   in	   addition	   to	   the	   caudal	  OB	  
because	  the	  AON	  is	  a	  major	  and	  obvious	  site	  of	  olfactory	  Lewy	  pathology	  in	  early	  Parkinson’s	  disease	  (Beach	  et	  al.,	  
2009;	  Braak	  et	  al.,	  2003;	  Daniel	  and	  Hawkes,	  1992;	  Rey	  et	  al.,	  2013;	  Ubeda-­‐Banon	  et	  al.,	  2010).	  Fibrils	  were	  infused	  
over	   the	  course	  of	  4	  minutes	   (0.25	  μL/min)	   followed	  by	  an	  additional	  4-­‐minute	  dwell	  period	  to	   facilitate	  diffusion	  
into	   brain	   parenchyma	   instead	   of	   up	   the	   needle	   track	   during	   withdrawal.	   During	   surgeries,	   animals	   were	   fully	  
anesthetized	  with	  2%	  vaporized	  isoflurane.	  All	  animals	  were	  placed	  on	  a	  warm	  pad	  until	  recovery	  from	  anesthesia.	  
For	  pain	  control,	  all	  animals	  were	  treated	  subcutaneously	  with	  0.1	  mg/kg	  buprenorphine	  immediately	  after	  surgery	  
and	  topical	  lidocaine	  on	  the	  incision	  for	  three	  days	  thereafter.	  	  
	  We	  injected	  fibrils	  or	  PBS	  in	  three	  separate	  studies	  to	  ensure	  the	  reproducibility	  of	  our	  observations	  (Study	  1,	  3,	  and	  
4).	   For	   the	   first	   study,	  2.5	  month-­‐old	  male	  CD1	  mice	  were	   infused	  with	  wildtype,	  mouse	  α-­‐synuclein	   fibrils	   (5	  µg;	  
n=10)	  or	  an	  equal	  volume	  of	  PBS	  (1	  µL;	  n=7)	   into	  the	  OB/AON.	  Six	  of	  the	  animals	   in	  the	  fibril	  group	  were	   injected	  
with	  1h	  waterbath-­‐sonicated	  fibrils	  and	  4	  animals	  were	  injected	  with	  1	  min	  probe-­‐sonicated	  fibrils.	  These	  mice	  were	  
sacrificed	  3	  months	   following	   fibril	   infusions.	   In	   the	   second	  part	  of	   the	   first	   study,	  we	   infused	  PBS	   (n=4)	  or	   fibrils	  
(n=4;	  5	  µg/1	  µL,	  1h	  waterbath-­‐sonicated)	  into	  the	  OB/AON	  of	  two	  month-­‐old	  animals	  and	  sacrificed	  the	  animals	  1.5h	  
later,	  as	  Rey	  and	  colleagues	  reported	  the	  most	  extensive	  spread	  of	  human	  α-­‐synuclein	  protein	  from	  the	  mouse	  OB	  
at	  this	  timepoint	  (Rey	  et	  al.,	  2013).	  For	  the	  third	  study,	  mice	  were	  infused	  in	  CA2/CA3	  of	  the	  hippocampus	  proper	  
with	   α-­‐synuclein	   fibrils	   (n=8;	   5	   µg)	   or	   an	   equal	   volume	   of	   PBS	   (1	   µL;	   n=4);	   for	   this	   experiment,	   the	   fibrils	   were	  
sonicated	  in	  the	  waterbath	  for	  either	  1h	  (n=4)	  or	  24h	  (n=4).	  We	  did	  not	  target	  CA1	  as	  in	  previous	  work	  (Luk	  et	  al.,	  
2012a),	  because	  CA2/CA3	   is	   a	  major	   site	  of	  hippocampal	   Lewy	  pathology	   in	  Parkinson’s	  disease	  and	  diffuse	   Lewy	  
body	   disease	   (Braak	   et	   al.,	   2003;	  Dickson	   et	   al.,	   1994;	   Flores-­‐Cuadrado	   et	   al.,	   2016).	   In	   the	   fourth	   study,	   animals	  
were	  infused	  in	  the	  OB/AON	  either	  with	  PBS	  (three	  5	  month-­‐old	  mice	  and	  three	  17	  month-­‐old	  mice)	  or	  5	  µg	  fibrils	  (in	  
1	  µL;	  three	  5	  month-­‐old	  mice	  and	  four	  17	  month-­‐old	  mice)	  sonicated	  for	  1h	  in	  a	  waterbath.	  In	  the	  fourth	  study,	  the	  
experimenter	  performing	   the	   stereotaxic	   infusions	  was	  completely	  blinded	   to	   the	   identity	  of	   the	   infusate	  and	   the	  
experimental	  group	  assignments.	  The	  mice	  in	  Study	  3	  and	  4	  were	  also	  sacrificed	  3	  months	  post-­‐infusion.	  
	  
3.	  FluoroGold	  transport	  to	  afferent	  sites	  
In	   Study	   2,	   the	  OB/AON	   of	   five	   2	  month-­‐old	  mice	  was	   infused	  with	   300	   nL	   of	   a	   1.5%	   solution	   of	   the	   retrograde	  
fluorescent	   tracer	  FluoroGold	   (FluoroChrome,	   LLC,	  Denver,	  CO)	   (Schmued	  and	  Fallon,	  1986;	  Wessendorf,	  1991)	  at	  
the	  same	  coordinates	  as	  used	  in	  the	  fibril-­‐injected	  animals	  (see	  Methods	  Section	  2	  above).	  Note	  that	  the	  sphere	  of	  
diffusion	  of	   a	   tracer	   through	   the	  parenchyma	  of	   the	  brain	   is	   expected	   to	  be	  more	  dependent	  upon	   the	   chemical	  
properties	  and	  concentration	  of	  the	   infusate	  than	  the	   initial	  volume	  of	   injection;	  the	  FluoroGold	   images	   inform	  us	  
about	   the	   location	   of	   the	   center	   of	   the	   injection,	   not	   the	   effective	   size	   of	   the	   fibril	   injection	   per	   se.	   One	   week	  
following	  stereotaxic	  infusions	  of	  FluoroGold,	  animals	  were	  perfused	  through	  the	  heart	  with	  saline	  and	  4%	  formalin	  
in	   0.1	  M	  phosphate	   buffer.	   Perfused	   brains	  were	   immersed	   in	   30%	   sucrose	   in	   10	  mM	  PBS	   for	   at	   least	   2d	   before	  
sagittal	  brain	  sections	  were	  collected	  on	  a	  freezing	  microtome.	  Free-­‐floating	  sections	  were	  stored	  in	  cryoprotectant	  
(Watson	  et	  al.,	  1986)	  at	  -­‐20	  oC	  until	  use.	  Cryoprotectant	  was	  washed	  off	  in	  PBS	  and	  sections	  were	  stained	  for	  1h	  at	  
room	   temperature	   with	   the	   infrared	   nuclear	   marker	   DRAQ5	   (1:10,000	   or	   0.5	   μM,	   Biostatus,	   Leicestershire,	   UK)	  
diluted	  in	  10	  mM	  PBS	  with	  0.3%	  Triton	  X-­‐100,	  mounted	  onto	  Superfrost	  Plus	  slides	  (Fisher	  Scientific,	  Pittsburgh	  PA),	  
dried,	  and	  coverslipped	  in	  FluoroMount	  G	  (Southern	  Biotech,	  Birmingham	  AL).	  Retrograde	  FluoroGold	  labeling	  and	  
DRAQ5-­‐stained	  nuclei	  were	  visualized	  under	  UV	  and	  CY5	  illumination	  with	  4×	  or	  10×	  objectives	  (Olympus	  IX73,	  B&B	  
Microscopes,	  Pittsburgh	  PA).	  Montages	  were	  stitched	  with	  CellSens	  software	  (Olympus).	  	  
	  
4.	  Histology	  and	  image	  analyses	  
Three	  months	   following	   fibril	  or	  PBS	   infusions,	  mice	  were	  perfused	  as	  above	  and	  free-­‐floating	  brain	  sections	   from	  
both	   groups	   were	   immunostained	   in	   parallel.	   Prior	   to	   the	   immunohistochemical	   procedures,	   cryoprotectant	   was	  
washed	   off	   in	   several	   exchanges	   of	   PBS	   and	   sections	   were	   heated	   to	   80	   oC	   in	   10	   mM	   sodium	   citrate	   tribasic	  
dihydrate	   (pH	   8.5)	   for	   30	   min	   for	   antigen	   retrieval	   (Jiao	   et	   al.,	   1999).	   Sections	   were	   then	   cooled	   to	   room	  
temperature,	  washed	   in	   PBS,	   and	   placed	   in	   a	   fish	   serum-­‐based	  Odyssey	   block	   (LiCor,	   Lincoln	  NE)	   for	   1h	   at	   room	  
temperature	  followed	  by	  overnight	  incubation	  in	  primary	  antibodies	  at	  4	  oC	  on	  a	  shaker.	  The	  blocking	  solution	  was	  
composed	   of	   50%	   Odyssey	   block	   in	   10	   mM	   PBS	   with	   0.3%	   Triton	   X-­‐100	   and	   was	   also	   used	   for	   all	   antibody	  
incubations.	  Following	  overnight	   incubation,	  unbound	  primary	  antibodies	  were	  rinsed	  off	  with	  three	  exchanges	  of	  
PBS	  and	  sections	  were	   incubated	   in	  secondary	  antibodies	   for	  1h	  at	   room	  temperature.	  All	  primary	  and	  secondary	  
antibodies	  are	   listed	   in	  Table	   S3.	  Nuclei	  were	  stained	  with	  Hoechst	  and/or	  DRAQ5	  reagents	  during	   the	  secondary	  
antibody	   incubation	   period.	   Following	   three	   final	  washes	   in	   PBS,	   sections	  were	  mounted	   onto	   glass	   slides,	   dried,	  
coverslipped,	  and	  viewed	  with	  epifluorescent	  microscopy.	   Images	  were	  captured	  using	  4×,	  10×,	  40×,	  or	  100×	   (oil)	  
objectives.	  Grayscale	  images	  (12-­‐bit	  depth)	  were	  pseudocolored	  for	  presentation.	  	  
	  
For	  the	  inclusion	  count	  measurements	  on	  young	  animals	  (Study	  1),	  the	  final	  n	  was	  4-­‐5	  per	  group.	  One	  PBS-­‐infused	  
and	  1	  probe-­‐sonicated	  fibril-­‐infused	  animal	  died,	  1	  PBS	  animal	  was	  poorly	  perfused,	  and	  the	  OB	  of	  1	  animal	  injected	  
with	  waterbath-­‐sonicated	  fibrils	  was	  lost	  during	  processing.	  In	  the	  fourth	  study,	  one	  PBS-­‐infused	  animal	  in	  the	  oldest	  
group	  (17	  months	  of	  age)	  died.	  Raw,	  grayscale	  TIFF	  images	  were	  opened	  in	  ImageJ	  (NIH,	  Bethesda	  MD)	  and	  a	  blinded	  
observer	  used	  the	  threshold	  tool	  and	  the	  “analyze	  particles”	  function	  to	  count	  inclusion	  numbers	  in	  rhinencephalic	  
structures	   in	  PBS	  and	  fibril-­‐infused	  mice.	  Equivalent	  threshold	  values	  were	  always	  applied	  across	  all	   images	  during	  
this	  analysis.	  	  
	  
Schematized	   drawings	   were	   made	   with	   a	   Surface	   Tablet	   Pro	   (Microsoft,	   Redmond	   WA)	   on	   a	   large	   stitched	  
microscopic	   image	   of	   α-­‐synuclein,	   NeuN,	   or	   nuclear	   staining	   using	   freehand	   tools	   in	   Adobe	   Illustrator	   (Adobe	  
Systems,	  San	  Jose	  CA),	  while	  consulting	  the	  Paxinos	  and	  Franklin	  atlas	  (Franklin	  and	  Paxinos,	  2013)	  and	  zooming	  in	  
and	   out	   frequently	   to	   ensure	   correct	   delineation	   of	   cytoarchitectonic	   boundaries	   and	   inclusion	  morphology.	   The	  
style	  of	  the	  drawings	  was	  adapted	  from	  the	  Swanson	  brain	  atlas	  (Swanson,	  2004).	  
	  
5.	  Thioflavin	  S	  staining	  
The	  Thioflavin	  S	  staining	  protocol	  was	  adapted	  from	  work	  by	  Paumier	  and	  colleagues	  (Paumier	  et	  al.,	  2015).	  Sagittal	  
brain	  sections	  of	  mice	  from	  the	  OB/AON	  study	  were	  affixed	  on	  glass	  slides	  and	  immersed	  in	  10	  mM	  PBS	  for	  5	  min,	  
followed	  by	   immersion	   in	  0.05%	  KMnO4	  /	  PBS	  for	  20	  min.	  Following	  two	  rinses	   in	  PBS	  (2	  min	  each),	  sections	  were	  
destained	  in	  0.2%	  K2S2O5	  /	  0.2%	  oxalic	  acid	  /	  PBS	  until	  the	  brown	  color	  dissipated	  (~1	  min).	  Following	  five	  rinses	  in	  
PBS	  (2	  min	  each),	  sections	  were	  immersed	  in	  freshly	  filtered	  0.0125%	  Thioflavin	  S	  /	  40%	  EtOH	  /	  60%	  PBS	  for	  3	  min	  in	  
the	  dark.	  Finally,	  sections	  were	  differentiated	  in	  50%	  EtOH	  /	  50%	  PBS	  for	  10	  min,	  followed	  by	  four	  rinses	  in	  PBS	  (5	  
min	  each).	  Nuclei	  were	  stained	  with	  the	  Hoechst	  reagent	  (0.003	  μM;	  Hoechst	  33258,	  bisBenzimide)	  in	  0.3%	  Triton	  X-­‐
100	   during	   the	   last	   PBS	   wash,	   followed	   by	   a	   final	   5-­‐min	   rinse	   in	   deionized	   water.	   Stained	   sections	   were	   dried,	  
coverslipped,	  and	  viewed	  with	  epifluorescent	  microscopy	  as	  above.	  	  
	  
6.	  Controls	  for	  antibody	  specificity	  
The	   monoclonal	   and	   polyclonal	   pSer129	   antibodies	   led	   to	   the	   same	   inclusion	   staining	   patterns	   (see	   polyclonal	  
antibody	  staining	  in	  Fig.1F,	  Fig.S3,	  Fig.S6).	  The	  background	  staining	  with	  these	  two	  antibodies,	  especially	  along	  fiber	  
tracts,	   was	   also	   the	   same.	   We	   used	   the	   monoclonal	   antibody	   for	   the	   majority	   of	   our	   figures	   (unless	   indicated	  
otherwise)	  because	   it	   can	  be	  used	  at	   a	   far	   lower	  dilution	   at	   less	   cost.	   For	   the	  preadsorption	   controls	   for	  primary	  
antibody	   specificity,	   we	   used	   the	   polyclonal	   pSer129	   antibody,	   because	   preadsorption	   controls	   with	   monoclonal	  
antibodies	   are	   always	   expected	   to	   lead	   to	   less	   of	   signal	   regardless	  of	  which	  proteins	   the	   antibodies	   actually	   bind	  
within	  tissue	  (Saper,	  2005).	  For	  these	  control	  experiments,	  we	  incubated	  the	  polyclonal	  pSer129	  antibody	  with	  10-­‐
fold	  excess	  pSer129	  blocking	  peptide	  (Cat.no.	  188826,	  Abcam,	  Cambridge,	  MA)	  for	  24h	  at	  4	  oC	  prior	  to	  application	  to	  
tissue.	   Adjacent	   sections	   from	   the	   same	   animal	   were	   exposed	   in	   parallel	   to	   free	   primary	   antibodies	   or	   blocked	  
primary	  antibodies	  for	  24h	  at	  4	  oC,	  followed	  by	  secondary	  antibody	  incubations,	  washes,	  mounting,	  and	  microscopic	  
imaging	  as	  described	  above.	  To	  control	  for	  secondary	  antibody	  specificity,	  primary	  antibodies	  were	  omitted	  from	  the	  
immunohistochemical	  procedures	  and	  led	  to	  loss	  of	  fluorescent	  signal	  as	  expected.	  	  
	  
7.	  Confocal	  microscopy	  
Sagittal	  sections	   from	  animals	   infused	  with	  fibrils	   in	  the	  OB/AON	  were	  stained	  with	  pSer129	  and	  NeuN	  antibodies	  
and	   the	   Hoechst	   reagent	   as	   above	   and	   imaged	   on	   a	   confocal	  microscope	  with	   a	   40×	   oil	   objective	   using	   405nm,	  
488nm,	   561nm	   lasers	   (A1	   Confocal/Nikon	   Eclipse	   TiE	  motorized	   inverted	  microscope;	  Melville,	   NY).	   Labeling	  was	  
viewed	  with	  the	  NIS-­‐Elements	  C	  acquisition	  and	  analysis	  software	  platform.	  
	  
8.	  Electron	  microscopy	  
Fibrils—both	  untreated	  and	  sonicated—were	  visualized	  using	  whole-­‐mount	  preparations	  with	  transmission	  electron	  
microscopy.	   Samples	   were	   suspended	   on	   Formvar-­‐coated	   200	  mesh	   copper	   grids	   (Electron	  Microscopy	   Sciences,	  
Hatfield	  PA),	  and	  stained	  with	  1%	  uranyl	  acetate.	  Samples	  were	  then	  observed	  on	  a	   JEM-­‐1210	  TEM	  at	  60	  kV	  (Jeol	  
USA	   Inc.,	   Peabody	  MA)	  and	   images	  were	   captured	  using	  an	  ORCA-­‐HR	  digital	   camera	   (Hamamatsu,	  Middlesex	  NJ).	  
Fibrils	   were	   both	   negatively	   and	   positively	   stained	   with	   uranyl	   acetate,	   with	   much	   more	   positive	   than	   negative	  
staining	  in	  all	  the	  sonicated	  groups,	  as	  exemplified	  in	  the	  photomicrographs	  in	  Figure	  3D.	  
	  
9.	  Statistical	  analyses	  	  
Data	   are	   presented	   in	   figures	   as	   the	  mean	   +	   SEM.	   The	   unpaired	   Student’s	   t	   test	  was	   employed	   for	   the	   inclusion	  
count	  measurements.	  All	  measurements	  were	  blinded.	   	  
1	  	  
Table	  S1:	  Abbreviations	  
5N	   	   motor	  trigeminal	  nucleus	  
7n	  	   	   facial	  nerve	  
7N	  	   	   facial	  nucleus	  
8n	  	   	   vestibulocochlear	  nerve	  
AA	  	   	   anterior	  amygdaloid	  area	  
ac	  	   	   anterior	  commissure	  
aca	  	   	   anterior	  commissure,	  anterior	  part	  
Acb	  	   	   nucleus	  accumbens	  
aci	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  anterior	  commissure,	  intrabulbar	  
acp	  	   	   anterior	  commissure,	  posterior	  part	  
AHi	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  amygdalohippocampal	  area	  
AMG	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  amygdala	  
AOB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  accessory	  olfactory	  bulb	  
AOD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  anterior	  olfactory	  area,	  dorsal	  
AOE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  anterior	  olfactory	  nucleus,	  external	  
AOM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  anterior	  olfactory	  nucleus,	  medial	  
AON	   	   anterior	  olfactory	  nucleus	  
AOP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  anterior	  olfactory	  area,	  posterior	  
AOV	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  anterior	  olfactory	  area,	  ventral	  
APir	  	   	   amygdalopiriform	  transition	  area	  
AV	  	   	   anteroventral	  thalamic	  nucleus	  
BLA	  	   	   basolateral	  nucleus	  of	  amygdala	  
BMA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  basomedial	  nucleus	  of	  amygdala	  
CA1	  	   	   cornu	  ammonis,	  field	  1	  
CA3	  	   	   cornu	  ammonis,	  field	  3	  
cc	  	   	   corpus	  callosum	  
CEA	  	   	   central	  nucleus	  of	  amygdala	  
cp	  	   	   cerebral	  peduncle	  
CPu	  	   	   caudoputamen	  
cst	  	   	   commissural	  stria	  terminalis	  
DG	  	   	   dentate	  gyrus	  
Ect	  	   	   ectorhinal	  cortex	  
Ent	  	   	   entorhinal	  cortex	  
EPl	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  external	  plexiform	  layer,	  olfactory	  bulb	  
FC	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  frontal	  cortex	  
fi	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  fimbria	  
fmi	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  forceps	  minor	  of	  the	  corpus	  callosum	  
fr	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  fasciculus	  retroflexus	  	  	  	  	  	  	  
Gl	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  glomerular	  layer,	  olfactory	  bulb	  
GP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  globus	  pallidus	  
GrO	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  granule	  cell	  layer	  of	  olfactory	  bulb	  
HDB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  horizontal	  limb	  of	  the	  diagonal	  band	  
HP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  hippocampus	  
ic	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  internal	  capsule	  
IC	  	   	   inferior	  colliculus	  
LH	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  lateral	  habenula	  
lo	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  lateral	  olfactory	  tract	  
LOT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  nucleus	  of	  the	  lateral	  olfactory	  tract	  
Lrt	  	  	   	   lateral	  reticular	  nucleus	  
LSd	  	   	   lateral	  septal	  nucleus,	  dorsal	  part	  
LSv	  	   	   lateral	  septal	  nucleus,	  ventral	  part	  
LTDg	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  laterodorsal	  tegmental	  nucleus	  
LV	  	   	   lateral	  ventricle	  
M2	  	   	   secondary	  motor	  cortex	  
MD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  mediodorsal	  thalamic	  nucleus	  
MEA	  	   	   medial	  amygdala	  
mlf	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  medial	  longitudinal	  fasciculus	  
OB	  	   	   olfactory	  bulb	  
och	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  optic	  chiasm	  
ot	  	   	   optic	  tract	  
Pir	  	   	   piriform	  cortex	  
PMCo	  	   	   posteromedial	  cortical	  amygdala	  
Pn	  	   	   pontine	  nuclei	  
Pr5	  	   	   principal	  trigeminal	  nucleus	  
rf	  	   	   rhinal	  fissure	  
rms	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  rostral	  migratory	  stream	  
S	  	   	   subiculum	  
S1	  	   	   primary	  somatosensory	  cortex	  
SC	  	   	   superior	  colliculus	  
sm	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  stria	  medullaris	  
sp	  	   	   spinal	  trigeminal	  tract	  
Sp	  	   	   spinal	  trigeminal	  nucleus	  
SVZ	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  subventricular	  zone	  
TeA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  temporal	  association	  cortex	  
TT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  tenia	  tecta	  
Tu	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  olfactory	  tubercle	  
VDB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ventral	  diagonal	  band	  
VM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ventromedial	  thalamic	  nucleus	  
VMH	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ventromedial	  hypothalamic	  nucleus	  





Table	  S2:	  Density	  of	  pSer129+	  or	  FluoroGold+	  label	  following	  α-­‐synuclein	  fibril	  or	  Fluorogold	  infusions	  into	  the	  OB/AON	  
	   	     α-­‐synuclein	  fibrils	  
FluoroGold	  
	   	   Probe-­‐sonicated	   Waterbath-­‐sonicated	  
	   	   2	  mo	   2	  mo	   2	  mo	   2	  mo	   2	  mo	   2	  mo	   2	  mo	   2	  mo	   5	  mo	   5	  mo	   5	  mo	   17	  mo	   17	  mo	   17	  mo	   17	  mo	   2	  mo	   2	  mo	   2	  mo	   2	  mo	   2	  mo	  
Region	   Hemisph.	   15-­‐327 15-­‐329 15-­‐330 15-­‐332 15-­‐333 15-­‐334 15-­‐340 15-­‐341 15-­‐439	   15-­‐441	   15-­‐443 15-­‐445 15-­‐447	   15-­‐449	   15-­‐451	   15-­‐452	   15-­‐453	   15-­‐454	   15-­‐455	   15-­‐456	  
Olfactory	  bulb	  
Ipsi	  (R)	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Contra	  (L)	   	   -­‐	   	   -­‐	   -­‐	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Anterior	  
olfactory	  nucleus	  
Ipsi	  (R)	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Contra	  (L)	   	   -­‐	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Frontal	  cortex	  
Ipsi	  (R)	   -­‐	   -­‐ -­‐    -­‐ -­‐ -­‐  -­‐  -­‐   -­‐     
Contra	  (L)	   -­‐ -­‐ -­‐ -­‐ -­‐   -­‐ -­‐  -­‐  -­‐ -­‐ -­‐ -­‐   -­‐ -­‐ 
Accumbens	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   	   -­‐	   	   	   	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Caudoputamen	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	   -­‐	   	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   	   -­‐	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Horizontal	  limb	  
of	  the	  diagonal	  
band	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   	   	   	   	   	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Olfactory	  
tubercle	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Piriform	  cortex	  
Ipsi	  (R)	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Contra	  (L)	   -­‐	   -­‐	   	   	   	   	   	   	   	   	   -­‐	   	   	   	   	   	   	   	   	   	  
Nucleus	  of	  the	  
lateral	  olfactory	  
tract	  
Ipsi	  (R)	   -­‐	   -­‐	   -	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  




Ipsi	  (R)	   -­‐	   -­‐	   -	   	   	   	   	   	   	   	   -­‐	   	   	   	   	   	   	   	   	   	  




Ipsi	  (R)	   	   -­‐	   -­‐	   	   	   	   	   	   	   	   -­‐	   	   	   	   	   	   	   	   	   	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   	   	   	   	   -­‐	   -­‐	   	   	   	   -­‐	   	   	   	   -­‐	   -­‐	   -­‐	   -­‐	  
Hippocampus	  	  
(CA1)	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	   	   	   	   	   	   	   	   -­‐	   	   	   	   	   	   	   	   	   	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   	   -­‐	   	   -­‐	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Hippocampus	  
(CA2/CA3)	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	       -­‐   -­‐ 	   -­‐   -­‐ -­‐ -­‐ -­‐ -­‐ 
Contra	  (L)	   -­‐	   -­‐	   -­‐	     -­‐  -­‐ -­‐ -­‐ -­‐ 	   -­‐  -­‐ -­‐ -­‐ -­‐ -­‐ -­‐ 
Hippocampus	  
(dentate	  gyrus)	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	   	   	   	   	   	   -­‐	   	   -­‐	   	   -­‐	   	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   	   	   	   -­‐	   -­‐	   -­‐	   	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Subiculum	  
Ipsi	  (R)	   -­‐	   -­‐	   -­‐	   	   	   	   	   	   	   	   -­‐	   	   	   	   	   	   	   	   -­‐	   	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   	   	   -­‐	   -­‐	   -­‐	   -­‐	   	   -­‐	   	   -­‐	   -­‐	   	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Entorhinal	  
cortex	  
Ipsi	  (R)	   	   -­‐	   -­‐	   	   	   	   	   	   	   	   -­‐	   	   	   	   	   	   	   	   	   	  
Contra	  (L)	   -­‐	   -­‐	   -­‐	   	   	   -­‐	   	   -­‐	   	   	   -­‐	   	   -­‐	   	   	   -­‐	   -­‐	   	   -­‐	   	  
CD1	  mice	  were	   infused	   in	  the	  OB/AON	  with	  recombinant,	  wildtype	  mouse	  α-­‐synuclein	  fibrils	  sonicated	  for	  1	  min	  with	  a	  probe	  or	  1h	   in	  a	  waterbath.	  Sagittal	  brain	  sections	  were	  stained	  with	  
pSer129	  antibodies	  3	  mo	  later.	  Separate	  mice	  were	  infused	  with	  FluoroGold	  in	  the	  OB/AON	  and	  sagittal	  brain	  sections	  were	  examined	  for	  retrogradely	  labeled	  cells	  7d	  later.	  Animal	  IDs	  are	  shown	  
in	  the	  fourth	  row.	  pSer129	  or	  FluoroGold	  labeling	  is	  semi-­‐quantitatively	  depicted	  in	  select	  regions	  in	  the	  ipsilateral	  (red)	  or	  contralateral	  (black)	  hemispheres	  from	  	  to	  (from	  sparsest	  to	  
densest)	  for	  individual	  mice	  (see	  Fig.1	  for	  statistical	  analyses	  of	  inclusion	  counts).	  Absence	  of	  label	  is	  depicted	  by	  “-­‐.”	  For	  examples	  of	  sparsest	  (one	  dot)	  to	  densest	  label	  (five	  dots)	  see	  
images	  directly	  below	  this	  table.	  The	  listed	  age	  of	  the	  animal	  is	  the	  age	  at	  infusion.	  All	  animals	  were	  sacrificed	  3	  mo	  following	  surgery	  (5,	  8,	  20	  months).	  This	  table	  was	  generated	  by	  a	  blinded	  
observer,	  with	  the	  exception	  of	  the	  label	  for	  the	  probe-­‐sonicated	  and	  FluoroGold-­‐infused	  animals,	  where	  it	  was	  obvious	  which	  group	  they	  belonged	  to.	  The	  variability	  in	  this	  table	  is	  typical	  of	  
tract-­‐tracing	   studies,	   and	   is	   likely	   explained	   by	   small	   variations	   in	   needle	   placement	   and	   differences	   in	   the	   sphere	   of	   diffusion	   of	   the	   infusate.	   Alternatively,	   there	  might	   be	   inter-­‐individual	  
variability	  in	  vulnerability	  to	  α-­‐synucleinopathy.	  Abbreviations	  in	  Table	  S1	  
	  
Table	  S3:	  Antibodies	  
	  
Primary	  Antibody	   Source	   Company	   Catalog	  #	   Lot	  #	   Dilution	  
Anti-­‐α-­‐synuclein	  (pSer129)	  
(aa	  124	  –	  134;	  AYEMPSpEEGYQ	  )	  
Mouse	   Gift	  from	  Kelvin	  Luk	  (81A)	  (Waxman	  and	  Giasson,	  2008)	   -­‐	   -­‐	   1:5000	  
Anti-­‐α-­‐synuclein	  (pSer129)	  
(aa	  127-­‐131;	  MPSpEE) Rabbit	   Abcam	   Ab59264	   GR52476-­‐25	   1:300	  
Anti-­‐total-­‐α-­‐synuclein	  
(aa	  1-­‐140)	  
Rabbit	   Abcam	   Ab155038	   GR117815-­‐9	  	   1:500	  
Anti	  K48-­‐linked	  ubiquitin	   Rabbit	   Millipore	   05-­‐1307	   2299608	   1:500	  
Anti	  K48-­‐linked	  ubiquitin	   Rabbit	   Cell	  Signaling	  Technology	   4289S	   1	   1:500	  
Anti-­‐NeuN	   Guinea	  pig	   Millipore	   ABN90	   2031353	   1:6000	  
	  
Secondary	  Antibody	   Source	   Company	   Catalog	  #	   Lot	  #	   Dilution	  
Anti-­‐guinea	  pig	  @	  790	   Donkey	   Jackson	  ImmunoResearch	   706-­‐655-­‐148	   106036	   1:1000	  
Anti-­‐guinea	  pig@	  647	   Donkey	   Jackson	  ImmunoResearch	   706-­‐605-­‐148	   123960	   1:700	  
Anti-­‐guinea	  pig	  @	  488	   Donkey	   Jackson	  ImmunoResearch	   706-­‐545-­‐148	   108077	   1:1000	  
Anti-­‐mouse	  @680	   Donkey	   Jackson	  ImmunoResearch	   715-­‐625-­‐151	   106244	   1:1000	  
Anti-­‐mouse	  @	  555	   Goat	   Invitrogen	   A21424	   1141876	   1:1000	  
Anti-­‐mouse	  @	  488	   Donkey	   Life	  Technologies	   A21202	   1423052	   1:800	  
Anti-­‐rabbit	  @	  647	   Donkey	   Jackson	  ImmunoResearch	   711-­‐605-­‐152	   123104	   1:1000	  
Anti-­‐rabbit	  @	  555	   Goat	   Life	  Technologies	   A21429	   1562309	   1:800	  
Anti-­‐rabbit	  @	  488	   Donkey	   Jackson	  ImmunoResearch	   711-­‐545-­‐152	   120705	   1:700	  
Anti-­‐rabbit@	  546	   Goat	   Life	  Technologies	   A11035	   1579044	   1:500	  
Anti-­‐mouse	  @	  488	   Goat	   Life	  Technologies	   A11029	   1550911	   1:500	  







Fig.S1	  Mice	  were	  infused	  in	  the	  OB/AON	  with	  PBS	  or	  5	  μg	  α-­‐synuclein	  fibrils	  (1	  min	  probe-­‐sonicated	  or	  1h	  waterbath-­‐sonicated).	  
Sagittal	  brain	   sections	  were	  collected	   three	  months	   later	  and	   labeled	  with	  pSer129	  antibodies	   (red)	  and	   the	  Hoechst	  nuclear	  
stain	  (blue).	  The	  densest	  pSer129	  label	  was	  in	  the	  AON	  and	  tenia	  tecta	  of	  the	  waterbath-­‐sonicated	  animals	  (shown	  above).	  Only	  




Fig.S2	  Mice	  were	   infused	   in	  the	  OB/AON	  with	  PBS	  or	  5	  μg	  α-­‐synuclein	  fibrils	   (1h	  waterbath-­‐sonicated).	  Sagittal	  brain	  sections	  
were	  collected	  three	  months	  later	  and	  labeled	  with	  pSer129	  antibodies	  (red)	  and	  the	  Hoechst	  nuclear	  stain	  (blue).	  The	  granule	  
cell	  layer	  of	  the	  dorsal	  OB	  is	  shown.	  Only	  few	  inclusions	  were	  present	  in	  the	  OB	  in	  fibril-­‐infused	  animals	  
	  
	  
	   	  
	  
Fig.S3	  Mice	  were	  infused	  in	  the	  OB/AON	  with	  PBS	  or	  5	  μg	  α-­‐synuclein	  fibrils	  (1h	  waterbath-­‐sonicated).	  Sagittal	  brain	  sections	  
were	  collected	  three	  months	  later.	  (A)	  Low	  power	  view	  of	  dense	  inclusions	  in	  the	  OB/AON,	  labeled	  with	  the	  polyclonal	  pSer129	  
antibodies	  (red).	  The	  DRAQ5	  nuclear	  stain	  (purple)	  was	  applied	  to	  reveal	  cytoarchitectonic	  boundaries.	  (B)	  Polyclonal	  pSer129	  
antibodies	  (red)	  and	  monoclonal	  pSer129	  antibodies	  (green)	  were	  applied	  simultaneously	  and	  visualized	  with	  distinct	  secondary	  
antibodies.	   The	   merged	   image	   does	   not	   include	   the	   DRAQ5	   staining	   because	   it	   overwhelmed	   the	   other	   labeling.	   A	   limited	  
number	  of	  immunoreactive	  structures	  exhibited	  more	  staining	  with	  one	  antibody	  or	  the	  other,	  perhaps	  reflecting	  heterogeneity	  
of	   the	   antibody	   clones,	   exposure	   of	   distinct	   epitopes	  within	  misfolded,	   aggregated	   protein	   clumps,	   or	   competition	   between	  




Fig.S4	  Mice	  were	  infused	  in	  the	  OB/AON	  with	  PBS	  or	  α-­‐synuclein	  fibrils	  (1h	  waterbath-­‐sonicated).	  Sagittal	  brain	  sections	  were	  
collected	  three	  months	   later	  and	   labeled	  with	  the	  Thioflavin	  S	  stain	   for	  amyloid	   (green)	  and	  the	  Hoechst	  nuclear	  stain	   (blue).	  
Amyloid	  staining	  was	  apparent	  at	  the	  site	  of	  fibril	  injection	  in	  the	  dorsal	  OB/AON	  only.	  AOB,	  accessory	  olfactory	  bulb	  
	   	  
	  
	  
Fig.S5	  Mice	  were	   infused	   in	   the	   hippocampus	  with	  α-­‐synuclein	   fibrils	   (1h	  waterbath-­‐sonicated).	   Coronal	   brain	   sections	  were	  
collected	  three	  months	  later	  and	  labeled	  for	  K48-­‐linked	  polyubiquitin	  (green),	  pSer129	  (red),	  and	  the	  neuronal	  nuclear	  marker	  
NeuN	   (blue).	   Some	   but	   not	   all	   pSer129+	   structures	   in	   the	   amygdala	   (shown)	   contained	   dense	   K48-­‐linked	   polyubiquitin.	   This	  
figure	  shows	  the	  staining	  with	  the	  Cell	  Signaling	  Technologies	  anti-­‐ubiquitin	  antibody.	  Figure	  2D	   in	  the	  main	  text	  shows	  much	  




























Fig.S6	  Mice	  were	   infused	   in	   the	   hippocampus	  with	   5	   μg	   α-­‐synuclein	   fibrils	   (1h	  waterbath-­‐sonicated).	   Coronal	   brain	   sections	  
were	   collected	   three	   months	   later.	   Adjacent	   brain	   sections	   from	   the	   same	   animal	   were	   exposed	   either	   to	   free,	   unbound	  
pSer129	  polyclonal	  antibodies	  or	  preadsorbed	  pSer129	  polyclonal	  antibodies.	  Preadsorption	  reduced	  the	  staining	  of	  inclusions	  
(top	  panels).	  For	  the	  preadsorption	  control	  on	  OB/AON	  tissue,	  please	  examine	  Fig.1F.	  CA2/CA3,	  cornu	  or	  corpus	  ammonis;	  DG,	  
dentate	  gyrus	   	  
	  
	  
Fig.S7	  Mice	  were	  infused	  with	  α-­‐synuclein	  fibrils	  (24h	  waterbath-­‐sonicated)	  into	  CA2/CA3	  of	  the	  hippocampus	  and	  sacrificed	  3	  
months	  later.	  Coronal	  brain	  sections	  were	  stained	  with	  Hoechst	  (blue)	  and	  antibodies	  against	  pSer129	  (red).	  The	  most	  inclusions	  
were	  observed	   in	   the	  dentate	   gyrus	   (DG)	   and	  CA3	   (see	  white	  horizontal	   arrow).	   Sparse	   inclusions	  were	   also	  observed	   in	   the	  
entorhinal	  cortex	  (Ent;	  white	  diagonal	  arrow).	  Please	  zoom	  into	  the	  figure	  to	  distinguish	  the	  inclusions	  from	  background	  label	  
	   	  
	  	  
	  
Fig.S8	  Mice	  were	   infused	  with	  phosphate-­‐buffered	   saline	   (PBS)	   into	   the	  OB/AON.	   Three	  months	   later,	   sagittal	   brain	   sections	  
were	  collected	  and	  stained	  for	  DRAQ5	  (A,	  C,	  E,	  G,	   I,	  K,	  M)	  and	  pSer129	  (B,	  D,	  F,	  H,	   J,	   L,	  N).	  Panels	  A-­‐B,	  E-­‐F,	  I-­‐J,	  M-­‐N	  illustrate	  
animals	   infused	  with	  PBS	  at	  17	  months	  of	  age	  and	  sacrificed	  at	  20	  months.	  The	  remaining	  panels	   illustrate	  animals	  that	  were	  
infused	  at	  5	  months	  of	  age	  and	  sacrificed	  at	  8	  months.	  The	  exposure	  times	  for	  all	  the	  microscopy	  in	  this	  study	  was	  purposefully	  
long	   so	   that	   all	   the	   background	   staining	   (particularly	   of	   fiber	   tracts)	   and	   the	   cytoarchitectonic	   boundaries	   could	   be	   properly	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